KR20230011282A - 신규 흡입제 - Google Patents

신규 흡입제 Download PDF

Info

Publication number
KR20230011282A
KR20230011282A KR1020227038651A KR20227038651A KR20230011282A KR 20230011282 A KR20230011282 A KR 20230011282A KR 1020227038651 A KR1020227038651 A KR 1020227038651A KR 20227038651 A KR20227038651 A KR 20227038651A KR 20230011282 A KR20230011282 A KR 20230011282A
Authority
KR
South Korea
Prior art keywords
cepharantin
inhalation
powder
inhalant
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227038651A
Other languages
English (en)
Korean (ko)
Inventor
무츠오 오쿠무라
세이이치 무라카미
Original Assignee
교와 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 교와 가부시키가이샤 filed Critical 교와 가부시키가이샤
Publication of KR20230011282A publication Critical patent/KR20230011282A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227038651A 2020-05-14 2021-05-14 신규 흡입제 Withdrawn KR20230011282A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020085471 2020-05-14
JPJP-P-2020-085471 2020-05-14
PCT/JP2021/018328 WO2021230340A1 (ja) 2020-05-14 2021-05-14 新規吸入剤

Publications (1)

Publication Number Publication Date
KR20230011282A true KR20230011282A (ko) 2023-01-20

Family

ID=78524492

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038651A Withdrawn KR20230011282A (ko) 2020-05-14 2021-05-14 신규 흡입제

Country Status (8)

Country Link
US (1) US20230338365A1 (https=)
EP (1) EP4151211A1 (https=)
JP (1) JPWO2021230340A1 (https=)
KR (1) KR20230011282A (https=)
CN (1) CN117083063A (https=)
AU (1) AU2021270426A1 (https=)
PH (1) PH12022553084A1 (https=)
WO (1) WO2021230340A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
JP2024178477A (ja) * 2021-11-04 2024-12-25 興和株式会社 カプセル剤
JP2024178478A (ja) * 2021-11-04 2024-12-25 興和株式会社 医薬品
CN118555958A (zh) * 2021-11-17 2024-08-27 国立感染症研究所所长代表的日本国 含有来自金线吊乌龟的生物碱的制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1201737C (zh) * 2003-06-19 2005-05-18 广州暨南生物医药研究开发基地有限公司 千金藤素在制备抗sars病毒药物中的应用
WO2007011396A2 (en) * 2004-10-29 2007-01-25 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
CN1771953A (zh) * 2005-11-01 2006-05-17 袁继民 一种含有千金藤素的药物
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
CN110151691A (zh) * 2019-06-19 2019-08-23 宁夏医科大学 一种千金藤素纳米混悬液及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
https://www.tus.ac.jp/mediarelations/archive/20200422_9837.html

Also Published As

Publication number Publication date
WO2021230340A1 (ja) 2021-11-18
CN117083063A (zh) 2023-11-17
JPWO2021230340A1 (https=) 2021-11-18
AU2021270426A1 (en) 2022-12-08
US20230338365A1 (en) 2023-10-26
EP4151211A1 (en) 2023-03-22
PH12022553084A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
KR20230011282A (ko) 신규 흡입제
US20220152145A1 (en) Method and formulation for inhalation
AU2002244211B2 (en) Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization
ES2745439T3 (es) Partículas micronizadas de agentes activos con baja potencia de dosificación para formulaciones en polvo para inhalación
TWI758617B (zh) 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途
US20020110529A1 (en) Inhalable powder containing tiotropium
AU2002244211A1 (en) Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization
Sansone et al. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying
HRP20000666A2 (en) Pulmonary and nasal delivery of raloxifene
TR201802921T4 (tr) Bir muskarinik reseptör antagonistinin ve bir beta-2 adrenoreseptör agonistinin kombinasyonları.
EP1660035A2 (en) Liquid compositions comprising formoterol
JP6919093B2 (ja) 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも１種の乾燥粉末を含む組成物
US12226384B2 (en) Peramivir solution type inhalant and preparation method therefor
JP2002532405A (ja) オピオイド吸入製剤
CN117205186B (zh) 一种雷芬那辛吸入喷雾剂及其制备方法
EP2957553A1 (en) Pharmaceutical formulations of vilanterol
CN114053216A (zh) 一种吸入用芜地溴铵溶液制剂及其制备方法
JP2024049405A (ja) 新規吸入剤
TW200922600A (en) DHEAS inhalation compositions
EP1494648B1 (en) Powder formulations suitable for inhalation
KR20240168342A (ko) 흡입에 의한 정신자극제 약물의 전달을 위한 방법 및 이 방법을 수행하기 위한 시스템
JP2024125434A (ja) 新規吸入剤
EP1169065A1 (en) Formulations for detecting asthma
CN116196298A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
WO2023068287A1 (ja) 新規医薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203